Multimodality Therapy Improves Survival in Resected Early Stage Gastric Cancer in the United States
| Autor: | John P. Plastaras, Luis Ignacio Ruffolo, Ronac Mamtani, Giorgos C. Karakousis, Douglas L. Fraker, Robert E. Roses, Matthew T. McMillan, Lea Lowenfeld, Daniel T. Dempsey, Jashodeep Datta, Jeffrey A. Drebin |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Oncology medicine.medical_specialty medicine.medical_treatment Adenocarcinoma 03 medical and health sciences 0302 clinical medicine Gastrectomy Stomach Neoplasms Internal medicine medicine Adjuvant therapy Humans 030212 general & internal medicine Stage (cooking) Survival rate Aged Neoplasm Staging business.industry Cancer Middle Aged medicine.disease Combined Modality Therapy United States Surgery Survival Rate Radiation therapy Chemotherapy Adjuvant 030220 oncology & carcinogenesis Female Radiotherapy Adjuvant Guideline Adherence business Adjuvant Chemoradiotherapy |
| Zdroj: | Annals of Surgical Oncology. 23:2936-2945 |
| ISSN: | 1534-4681 1068-9265 |
| DOI: | 10.1245/s10434-016-5224-1 |
| Popis: | National guidelines endorse adjuvant chemotherapy ± radiotherapy (C ± RT) for early-stage gastric cancer (ESGC). Compliance with these guidelines and the specific impact of adjuvant C ± RT on overall survival (OS) in ESGC have not been extensively explored. The National Cancer Data Base was queried for stage IB-II gastric adenocarcinoma patients undergoing gastrectomy (1998–2011). Multivariable modeling identified factors associated with adjuvant C ± RT receipt and compared risk-adjusted OS by treatment type (i.e., adjuvant therapy versus surgery alone). Of 23,461 ESGC patients (1998–2011), 79.4 % and 20.6 % received surgery alone and adjuvant C ± RT (chemoradiotherapy 17.7 %; chemotherapy alone 2.9 %), respectively. Predictors of adjuvant C ± RT receipt included age |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink